CICP & VICP Data Resources

Claims breakdown by vaccine manufacturer and other COVID countermeasures

Claims categorized by injury type (myocarditis, GBS, etc.)

Annual filing trends for COVID-19 countermeasure claims

Detailed compensation data including injury type and amount paid

Claims denied due to missing medical documentation

Claims denied for missing 1-year filing deadline

Claims denied on medical/scientific evidence grounds

Claims for products not covered under PREP Act declarations

H1N1, smallpox, anthrax, and other countermeasure claims

Appeals data showing outcomes of reconsideration reviews

Official side-by-side comparison of both programs

Program overview and filing guidance for claimants

Frequently asked questions about CICP eligibility and process

Official claim submission form for CICP

Third-party tool correlating COVID-19 vaccine batch codes with VAERS adverse event reports. Maintained independently by Frank Knoll. Not affiliated with this site; methodology and conclusions are the author's own.

Full bill text — raises special masters to 10+, adds COVID vaccines to VICP, increases excise to $2.20

Published decisions from the Office of Special Masters

Searchable database of VICP case decisions

Congressional Research Service analysis of CICP structure and issues

Congressional Research Service analysis of VICP and Special Masters

Office of Special Masters budget: $10M/yr for 8 masters (~$1.25M per master fully loaded)

Statutory salary caps — Chief Special Master: Executive Schedule Level IV ($197K); others: Level V ($185K)

Statutory framework for the Trust Fund including administrative expense caps and excise tax provisions

Current salary rates: Level IV ($197,200) and Level V ($184,900) — sets special master pay

Journal of Law & Biosciences article on CICP reform options and Trust Fund interest income

December 2024 GAO report on CICP challenges and recommendations

GAO report on VICP administrative costs across three agencies (USCFC, HRSA, DOJ) with staffing data

Inspector General reports on vaccine compensation programs

Official regulations governing CICP administration

Current list of all PREP Act covered countermeasures

Petitions filed, adjudications, awards paid, and dose distribution — primary source for H.R. 5142 financial model

Historical statistics reports dating back to program inception

Official table of covered vaccines and presumptive injuries

Detailed breakdown of petition outcomes by vaccine type

Most recent major Federal Register table revision

Comprehensive program guide for petitioners

Frequently asked questions about VICP eligibility and process

Required forms for filing VICP petitions

GBS rates of 4.4-6.5 per million doses in adults 60+ — used for new vaccine claim projections

January 2025 safety communication requiring GBS warning on Abrysvo and Arexvy